Dr. Philipp Dohnke

关于 Dr. Philipp Dohnke

Philipp is a member of our intellectual property and information technology team.

Since joining the firm, he has worked across many industries with a particular focus on life science and technologies. Philipp has broad expertise in complex, high-profile transactions, including large carve-out and asset deal projects. In addition, Philipp is experienced in drafting and negotiating complex commercial contracts.

近期项目经验

• Merck on the sale of its Surface Solutions Business to Global New Material International Holdings Ltd.
• Barclays on the sale of its German consumer finance business to Austria-based BAWAG Group
• Näder Holding GmbH & Co. KG on the repurchase of 20% of the shares in Ottobock SE & Co. KGaA from the Swedish private equity firm EQT and a new refinancing of Näder Holding
• Airbus on its acquisition of INFODAS
• Deutz on the acquisition of a diesel engine business from Rolls-Royce Power Systems
• Continental on the sale of its manufacturing site in Kaluga, Russia (as part of Continental's announced controlled exit from the Russian market)
• Schenck Process Group on the $730M Sale to Hillenbrand of its Food and Performance Materials Business
• Cinven on its acquisition of MBCC Group’s Admixtures business from Sika AG
• Eppendorf SE on the sale of its micro manipulation product portfolio to Calibre Scientific
• Deutz on the acquisition of IP and license rights as well as a collaboration with Daimler Truck in the field of medium- and heavy-duty engines
• Grünenthal on a joint venture collaboration with Kyowa Kirin International
• Affimed on a strategic cooperation with Artiva Biotherapeutics for the joint development of a combination therapy in the field of immuno-oncology
• Umicore on the creation of a joint venture with PowerCo SE, the Volkswagen AG battery subsidiary, to establish the first large-scale supply chain for sustainable batteries for electric vehicles in Europe
• Grünenthal on its €500m acquisition of testosterone business ("Nebido") from Bayer
• Special Olympics World Games Berlin 2023 Organisationskomitee gGmbH on the World Games and the National Games in advance, both taking place in Berlin on contractual and intellectual property related matters
• International Chemical Investors Group (ICIG) on their sale of CordenPharma (leading global CDMO (contract development & manufacturing organization)) to European private equity firm Astorg
• Osram on the carve-out and sale of its Digital Systems business in North America to Acuity
• Thermo Fisher on its €725m acquisition of the viral vector manufacturing business of Novasep (Belgium)
• AstraZeneca on its $39bn acquisition of Alexion Pharmaceuticals
• Charterhouse / Serb on the $800m acquisition of the BTG Specialty Pharmaceuticals business from Boston Scientific Corporation
• Novartis on its $5.2bn acquisition of pharmaceutical product Xiidra from Takeda/Shire
• Merck on its €3.4bn carve-out und sale of its consumer health business to Procter & Gamble
• Boehringer Ingelheim on its €18bn business swap with Sanofi (Consumer Healthcare against Animal Health)
• Boehringer Ingelheim on its sale of rights in the pharmaceutical product Buscopan in Brazil to Hypera
• AstraZeneca / MedImmune on the acquisition of Definiens AG
• BioNTech on license deals and other collaborations in the field of mRNA products / individualized medicines (including with Pfizer, Genentech, Sanofi, Eli Lilly, Bayer Animal Health and Genmab)
• Advent International on the $1.9bn acquisition of Sanofi's generics business (Zentiva) and on the add-on acquisition of Alvogen's CEE business
• Bridgepoint on the acquisition of Pharmazell (manufacturer of active pharmaceutical ingredients)
• BC Partners on the €2.6bn acquisition of CeramTec
• BC Partners on the acquisition of a majority stake in the Greek generics company Pharmathen
• Charterhouse / Cooper on the acquisition of a consumer health product portfolio from Sanofi
• Charterhouse / Serb on the acquisition of rights in a pharmaceutical product from a US biotech company
• CVC on the acquisition of a 50% stake in the pharmaceutical excipient manufacturer DFE Pharma from Fonterra (Joint Venture with FrieslandCampina)
• Cinven/Hotelbeds on the acquisition of the Global Travel Distribution business from Kuoni
• Continental on the carve-out of its powertrain business ("Vitesco Technologies")
• Deutsche Bank on the carve-out and listing of its Asset Management business ("DWS")
• H.I.G. on the carve-out and acquisition of the European polyutherane "system house" business from Covestro
• Hellman & Friedman on its €2.9bn acquisition of the internet platforms AutoScout24, FinanceScout24 und Finanzcheck